My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Surmodics, Inc. - Common Stock (NQ:SRDX)

42.98 UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

March 05, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

SRDX NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

March 03, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, A TOP RANKED LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

February 26, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

February 23, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, A LEADING LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

February 19, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

February 09, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Surmodics, Inc. (NASDAQ:SRDX) Investor Alert: Investigation over Possible Violations of Securities Laws ↗

February 07, 2023

San Diego, CA -- (SBWIRE) -- 02/07/2023 -- An investigation was announced over potential securities laws violations by Surmodics, Inc. in connection with certain financial statements.

Via SBWire

Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

February 06, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics to Host Virtual Annual Meeting of Shareholders

January 31, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6

January 26, 2023

From Surmodics, Inc.

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm

January 23, 2023

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm

January 20, 2023

From The Schall Law Firm

Via Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Surmodics, Inc. (SRDX) Investigation

January 20, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

SRDX EQUITY ALERT: Rosen Law Firm Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

January 19, 2023

From Rosen Law Firm

Via Business Wire

Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference

January 19, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon

January 19, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18

January 16, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

November 17, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

November 11, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance

November 09, 2022

From Surmodics, Inc.

Via Business Wire

24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference

November 02, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th

October 28, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022

October 26, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics Announces New Credit Facilities Providing up to $125 Million in Financing

October 17, 2022

From Surmodics, Inc.

Via Business Wire

6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

October 11, 2022

From Surmodics, Inc.

Via Business Wire

6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe

October 07, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022

August 23, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics Reports Third Quarter Fiscal 2022 Results

July 27, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27

July 19, 2022

From Surmodics, Inc.

Via Business Wire

Surmodics to Present at Jefferies Healthcare Conference

June 01, 2022

From Surmodics, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.